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Nodal involvement is one of the most significant prognostic factors in squamous cell carcinoma (SCC) of the vulva. We conducted a
retrospective analysis of 31 women with histologically node-negative SCC from a population-based cohort of Grampian women.
Median follow-up was 42 months after radical vulvectomy with groin node dissection. In total, 13 women (42%) were found to have
micrometastases on immunohistochemistry. The risk of recurrence was almost 20-fold higher in those with micrometastases
compared to those without (hazard ratio¼19.6 (95% CI 2.3–171).
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Micrometastases, detected by imunohistochemistry (IHC) techni-
ques, have been implicated as a causative factor for recurrence in
node-negative patients with cancer. In breast cancer, for example,
the presence of micrometastases in axillary nodes is an indepen-
dent and a significant predictor of clinical outcome (Gray et al,
2001; Umekita et al, 2002). In cervical cancer, some preliminary
work has detected micrometastases in histologically negative
nodes (Van Trappen et al, 2001). They have been able to identify
micrometastases using real-time PCR and relate this to cytokeratin
19 to establish a molecular quantification and mapping of lymph
node micrometastases in cervical cancer. In terms of its clinical
relevence, Juretzka et al (2004) noted that two out of four patients
(50%) with micrometastases, who had previously histological
negative lymph nodes in cervical cancer recurred in contrast to
three out of 45 (7%) without micrometastases. Less is known about
the relationship of micrometastases in the inguinofemoral nodes of
patients with vulvar squamous cell carcinoma (SCC). Groin
lymphadenectomy is an inherent part of the management of vulval
cancer and women with histologically negative nodes are
considered to be optimally managed and do not receive adjuvant
therapy. Yet there is a 10–25% recurrence rate in this
circumstance (Malfetano et al, 1985; Gordinier et al, 2003).
Micrometastases may increase the risk of recurrence in vulval
cancer patients, but this has not been clearly demonstrated to date.
Our aim was to establish whether (1) micrometastases could be
identified in histologically negative groin nodes and (2) whether
there is an association between clinical recurrence and micro-
metastases.
MATERIALS AND METHODS
All women in Grampian Region who had a groin dissection for
vulval SCC with histologically negative nodes between 1988 and
1998 were identified from the Grampian Gynaecology Oncology
database. None of these patients had adjuvant radiotherapy.
Tumour blocks were identified from the pathology archive and the
histology reviewed to confirm diagnosis, staging, tumour features
and node negativity. All the lymph nodes were serially sectioned at
intervals of 250mm (mean four levels per block). Four sections
were made at each level, one stained with haematoxyllin and eosin
(H&E), one stained with a broad-spectrum anticytokeratin
monoclonal antibody (MNF 116) using immunohistochemistry
(IHC) and one negative control for IHC with one spare. Although
other molecular methods (Van Trappen et al, 2001) have been used
to detect occult metastases in lymph nodes, we chose cytokeratin
immunocytochemistry as this technique is relatively inexpensive
and simple. In addition, the pathologists in this study are
experienced in the interpretation of these preparations. Further-
more, from a laboratory standpoint, imunnocytochemistry is also
more widely available compared to methods such as polymerase
chain reaction. MNF116 was used as it demonstrated the most
consistent, selective and intense staining of the malignant
squamous cells and each of the lymph nodes was examined for
the presence of micrometastases (see Figure 1).
General data with respect to the diameter of the primary, depth
of invasion and the presence of coexisting lichen sclerosis or
vaginal intraepithelial neoplasia was documented (Table 1). The
site, number of cells and maximum diameter of the micrometa-
static deposits were recorded. Dates of recurrence and death were
obtained from the medical records. Data on the cause of death
were not universally available. Women contributed follow-up time
from the date of diagnosis with vulval SCC to date of
first recurrence, date of death or end of follow-up (generally the
date last seen on the clinic) whichever was the earliest. Cox
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sproportional hazard methods were used to compare the risk of
recurrence and the all-cause mortality in women with and without
recurrence. Hazard ratio was adjusted for age at diagnosis.
RESULTS
In total, 43 cases were identified but 12 were subsequently
excluded (case notes destroyed in eight, two cases no tumour, one
case blocks missing and in one no nodes were removed) leaving 31
women in the study group. The median age at diagnosis was 70
years (range 30–94). The mean number of lymph nodes removed
was 10 (range 2–19. The median duration of follow to recurrence
was 39 months (range 1–102) and to death was 42 months
(1–109). Nine women (29%) developed recurrent disease. On
reanalysis with standard H&E, one case of nodal involvement was
identified. After IHC staining, 13 (42%) of women were found to
have micrometastases. Eight of the nine women who relapsed were
in this group. Of the remaining 18 women without micrometas-
tases, only one recurred. The age-adjusted hazard ratio for
recurrence was 19.6 (CI 2.3–171) in those with micrometastases
compared to those without (Figure 2). Six of the 13 patients (46%)
with micrometastases had died compared to four of the 18 without
micrometastases (22%). The age-adjusted hazard ratio for survival
in those with micrometastases was 1.8 (CI 0.5–6.56), implying that
the risk was slightly raised in those with micrometastases, but this
did not reach significance and we were unable to look specifically
at deaths due to vulval SCC.
DISCUSSION
Our analysis demonstrates, firstly that micrometastases can be
clearly identified in histologically node-negative patients with
vulval cancer and, secondly and more importantly, that women
with micrometastases are at a significantly increased risk of
recurrence.
Two major issues of concern arising from the findings of this
study are the drive towards less radical surgery to avoid the well-
recognised morbidity associated with groin dissection and the
additional laboratory workload required in ultrastaging of lymph
nodes. There is considerable interest in examining the status of
sentinel nodes in vulval cancer in an attempt to reduce the need for
groin dissection. There has been a case reported of recurrence after
Figure 1 Micrometastases – cells in clusters.
Table 1 Patient’s characteristics with respect to nodal micrometastatic status
No micrometastases,
18 patients
Micrometastases,
13 patients
Total, 31
patients
Tumour diameter (cm) 0–2 10 6 16
2.1–4 4 3 7
44.1 3 4 7
Not recorded 1 0 1
Depth of invasion (mm) o14 0 4
1–10 12 10 22
410 1 3 4
Not recorded 1 0 1
Associated benign vulval conditions No lichen sclerosis or VIN 5 1 6
Lichen sclerosis 4 11 15
VIN 8 1 9
Both lichen sclerosis and VIN 1 0 1
Recurrence 18 9
Time (years)
8 7 6 5 4 3 2 1 0
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Figure 2 Relationship with time to recurrence and nodal status of
micrometastases (adjusted for age).
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ssentinel node dissection where subsequent analysis confirmed that
the negative sentinel node did contain micrometastases (Tamussino
et al, 2002). Marchiole et al (2004) found that three out of five
patients with nodal micrometastases in cervical cancer had tumour
cells in nonsentinel nodes despite having negative findings. The
high false negative rate with sentinel node biopsy in cervical cancer
raises concerns about the accurate identification of sentinel nodes
in this condition, which is in stark contrast to vulval cancer where
the identification of sentinel nodes has been extensively studied
with a higher predictive value. If less radical surgery for early stage
vulval cancer is to be undertaken then there is justification
for using serial sectioning and IHC staining in the sentinel node of
the groin bed in order to obviate the likelihood of recurrent
disease, as women with micrometastases may not receive optimal
treatment.
Our 42% detection rate of micrometastases in previously node-
negative patients is high compared to those in previous studies,
which were generally in the range of 10–25% (Malfetano et al,
1985). This could be due to by the serial sectioning methodology
with variable intervals between the levels examined as well as the
sensitivity of the IHC antibody used. Routine histological
examination in this historical cohort is likely to have been one
5-mm-thick section and indeed one macrometastasis was missed.
In our view, systematic serial sectioning and IHC is necessary to
identify micrometastases. Interpretation of IHC in lymph nodes
requires a degree of histopathological experience to discern true
staining of the rounded metastatic carcinoma cells from ano-
malous staining due to the reaction products of the IHC and weak
staining of interdigitating dendritic cells found in normal nodes.
Serial sectioning and staining with IHC requires time and expertise
and has cost implications. Further studies are necessary of larger
cohorts to confirm our findings. Moreover, studies are needed to
determine whether adjuvant therapy offers any advantage to
women diagnosed with vulval SCC, who are node negative and
have micrometatasses.
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